Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways
2005

Combining R115,777 and Tamoxifen to Fight Breast Cancer

publication Evidence: moderate

Author Information

Author(s): Dalenc Florence, Giamarchi Claire, Petit Mélissa, Poirot Marc, Favre Gilles, Faye Jean-Charles

Primary Institution: INSERM U563, CPTP, Département Innovation Thérapeutique et Oncologie Moléculaire, Toulouse, France

Hypothesis

Does the farnesyl-transferase inhibitor R115,777 enhance the effectiveness of tamoxifen in inhibiting MCF-7 cell growth through both estrogen receptor-dependent and independent pathways?

Conclusion

The study found that combining R115,777 with either selective estrogen receptor ligands or a selective anti-estrogen binding site ligand significantly increases their anti-proliferative effects on MCF-7 cells.

Supporting Evidence

  • R115,777 enhances the apoptotic effect of tamoxifen in MCF-7 cells.
  • The combination of R115,777 with tamoxifen resulted in a significant increase in apoptosis compared to either drug alone.
  • Isobologram analyses showed a synergistic effect between R115,777 and both ICI182,780 and PBPE.

Takeaway

Researchers tested a new drug, R115,777, with tamoxifen to see if they work better together to stop breast cancer cells from growing. They found that using both together is really effective.

Methodology

The study used the sulphorhodamine B assay to measure cell growth inhibition and evaluated apoptosis through various assays including flow cytometry.

Limitations

The study did not explore the effects of R115,777 on the cellular uptake of tamoxifen or the direct effects of R115,777 on apoptosis induction.

Digital Object Identifier (DOI)

10.1186/bcr1357

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication